Emil Kakkis loves orphans.
The former chief medical officer at BioMarin Pharmaceutical Inc. — the Novato-based poster child for developing treatments for so-called orphan drugs — is lining up cash and personnel for a new venture again aimed at rare diseases.
Whether Kakkis’ new company, Ultragenyx Pharmaceutical, can add to his string of successes depends largely on lining up financing. He hopes to have Series A funding of “substantially more” than $10 million secured by April and 20 to 25 employees by June.
The former chief medical officer at BioMarin Pharmaceutical Inc. — the Novato-based poster child for developing treatments for so-called orphan drugs — is lining up cash and personnel for a new venture again aimed at rare diseases.
Whether Kakkis’ new company, Ultragenyx Pharmaceutical, can add to his string of successes depends largely on lining up financing. He hopes to have Series A funding of “substantially more” than $10 million secured by April and 20 to 25 employees by June.
No comments:
Post a Comment